Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Rheumatology indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

ESR, CRP and inflammatory markers

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Do not use a normal ESR or CRP to defer assessment of suspected septic arthritis, giant-cell arteritis with visual symptoms, spinal infection, rapidly progressive vasculitis or another organ-threatening presentation. Clinical urgency and definitive investigation take precedence over a screening marker.

Purpose and principles

Interpret ESR, CRP and related inflammatory markers as context-dependent trends, recognising discordance, non-rheumatic causes and the conditions in which a normal result cannot safely close the diagnosis.

CRP rises after cytokine stimulation, especially interleukin-6, and falls as synthesis decreases. Its kinetics make it useful for following many acute inflammatory states, but immunomodulatory medicines that block relevant pathways may blunt the response. ESR measures how far red cells settle under standard conditions and changes more slowly. It is influenced by plasma proteins and red-cell number, shape and size, so it often remains elevated after the acute process improves.

Interpretation begins with pre-test probability and timing. In a hot swollen joint, aspiration and cultures answer the dangerous question; CRP only supports severity and trend. In suspected giant-cell arteritis, the combination of age, new headache, scalp tenderness, jaw symptoms, visual disturbance and vascular examination determines immediate action. A normal marker reduces probability but does not justify delay when vision is threatened.

Discordance is informative only after artefact and context are considered. Raised ESR with normal CRP may occur with anaemia, high immunoglobulins, renal disease or resolved inflammation. Raised CRP with normal ESR can occur early in infection or tissue injury. In systemic lupus erythematosus, CRP may be less elevated during some immune flares than expected, while infection can produce a stronger rise; this is a clue, not a diagnostic rule.

Monitoring should be tied to a decision. A falling CRP after source control can support response but cannot confirm eradication. Persistently raised markers in treated arthritis may reflect ongoing synovitis, infection, obesity or another disease. Conversely, normal markers with pain may reflect damage, fibromyalgia or active disease that is poorly captured by biomarkers. Always compare with joint counts, organ findings and functional trajectory.

Key points

  • CRP is a hepatic acute-phase protein that changes relatively quickly; ESR is an indirect sedimentation measure affected by fibrinogen, immunoglobulins, red-cell characteristics, age and pregnancy.
  • Neither test is specific for rheumatic disease: infection, cancer, trauma, tissue injury and obesity can raise inflammatory markers.
  • Normal markers do not exclude rheumatoid arthritis, axial spondyloarthritis, giant-cell arteritis, infection or connective-tissue disease when the phenotype remains convincing.
  • ESR may remain raised with anaemia, paraproteinaemia, renal disease or older age even when CRP and clinical inflammation are modest.
  • An isolated high CRP with relatively normal ESR may reflect early acute inflammation because CRP responds faster, but timing and laboratory ranges matter.
  • Use trends only when the same clinical question persists; repeating markers without examining the patient can create false reassurance or unexplained surveillance.
  • Disease activity scores may incorporate markers, but patient pain and comorbidity can diverge from synovitis; combine scores with examination and function.
  • A very high or unexpectedly persistent inflammatory response should reopen infection, malignancy and tissue injury rather than automatically prompting more immunosuppression.

Indications, selection and cautions

Acute CRP-dominant riseRed flag

A rapid CRP increase with systemic illness supports an acute inflammatory or infectious process and should be interpreted alongside cultures, imaging and organ function.

Disproportionately raised ESR

Anaemia, paraproteins, renal disease, pregnancy and age can increase ESR independently, especially when CRP and examination do not show comparable inflammation.

Normal-marker inflammatory disease

Objective synovitis, inflammatory back pain or compatible vascular symptoms can occur with normal values, so clinical referral and definitive testing may still be required.

Unexpected persistent elevation

Markers that remain high despite apparently controlled rheumatic disease should prompt review for occult infection, malignancy, tissue injury and treatment adherence before escalation.

Marker–symptom discordance

Severe pain with low objective inflammation may reflect structural damage or pain amplification, while limited symptoms can coexist with silent organ inflammation.

Method and interpretation

  1. 01
    C-reactive proteinFirst step
    Why
    Quantify a rapidly responsive acute-phase signal and follow a defined inflammatory trajectory.
    Interpretation and limitations
    Use the laboratory reference range and timing. A normal result cannot exclude important disease, and cytokine-targeted treatment may alter the expected response.
  2. 02
    Erythrocyte sedimentation rate
    Why
    Provide an indirect, slower inflammatory measure that can be useful in selected longitudinal and paraprotein-associated contexts.
    Interpretation and limitations
    Adjust interpretation for age, anaemia, pregnancy, renal disease, immunoglobulins and red-cell abnormalities; do not treat ESR as a disease-specific test.
  3. 03
    Full blood count and film when indicated
    Why
    Identify anaemia, cytopenia, leucocytosis and red-cell features that explain disease severity or distort ESR.
    Interpretation and limitations
    Anaemia can raise ESR and may indicate chronic inflammation, blood loss, haemolysis, marrow disease or renal dysfunction requiring its own work-up.
  4. 04
    Serum protein electrophoresis and immunoglobulins
    Why
    Investigate an unexplained high ESR, protein gap, anaemia, renal impairment or symptoms suggesting paraproteinaemia.
    Interpretation and limitations
    Polyclonal elevation occurs in inflammation; a monoclonal component requires haematology-aligned confirmation and risk assessment rather than attribution to arthritis.

Clinical next steps

01Dangerous phenotypeAct on the syndrome, not the markerFirst stepSeptic joint, threatened vision, systemic vasculitis or spinal infection remains clinically plausible regardless of ESR or CRP.+
  1. 1DefinitivePerform urgent clinical and organ assessment, obtain the definitive samples or imaging and involve the responsible specialist without waiting for repeat markers.
  2. 2Begin time-critical treatment according to the relevant pathway when delay risks joint, vision, neurological or organ loss.
  3. 3Use serial markers only as one component of response alongside physiology, examination, microbiology, imaging and organ function.
02Discordant resultExplain the biology before repeatingESR and CRP disagree substantially or conflict with the examination and symptom trajectory.+
  1. 1Check timing, laboratory range, anaemia, pregnancy, renal disease, obesity, medicines and recent infection or tissue injury.

Risks, monitoring and follow-up

  • Plot marker values against symptoms, examination, treatment and intercurrent infection rather than reading an isolated number.
  • Review FBC, renal and liver profiles when they explain ESR or represent organ involvement and medicine toxicity.
  • Record the clinical question and intended action whenever markers are repeated.
  • Reassess for infection before increasing immunosuppression in response to unexpectedly raised values.
  • Stop routine repeat testing when no decision depends on the result and provide clinical safety-netting instead.

Special situations

ESR is a systems measurement

It reflects plasma proteins and red-cell behaviour as well as inflammation, explaining why anaemia and paraproteins can dominate the result.

CRP kinetics matter

A result drawn early may precede a rise, while a falling value after treatment can lag behind or fail to reveal residual local infection.

Biologics can change the signal

Therapies targeting inflammatory cytokines may blunt acute-phase responses, so infection assessment must not depend on the expected CRP alone.

Normal is not exclusionary

Reference intervals describe populations; important inflammatory disease can remain within them when the clinical phenotype is strong.

Trends need a comparator

Serial values become meaningful only when timing, assay, treatment and the clinical state are sufficiently comparable.

Common pitfalls

  1. 01

    Reassuring a patient with threatened-vision symptoms because inflammatory markers are normal.

  2. 02

    Increasing immunosuppression for a high CRP without reconsidering infection.

  3. 03

    Calling an isolated raised ESR proof of polymyalgia rheumatica or another rheumatic diagnosis.

  4. 04

    Repeating markers weekly without specifying what result will change management.

  5. 05

    Ignoring anaemia, renal disease or paraproteins that explain ESR discordance.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RheumatologyOriginal SBA

Normal markers with synovitis

A patient has persistent objective MCP and wrist synovitis but normal ESR and CRP on two occasions. What is the most appropriate interpretation?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Rheumatology topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG100 rheumatoid arthritisReferral and use of inflammatory markers in persistent synovitis.
  • NICE NG65 spondyloarthritisNormal inflammatory markers do not exclude spondyloarthritis.
  • NICE NG253 suspected sepsis in people aged 16 or overClinical risk and definitive assessment take priority in suspected infection.
  • NICE NG12 suspected cancerInvestigation of unexplained findings that may indicate myeloma or malignancy.
  • British Society for Rheumatology guidelinesSpecialist guidance relevant to giant-cell arteritis and interpretation of inflammatory disease activity.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • 05
    Disease-specific definitive tests
    Why
    Answer the actual diagnostic question when inflammatory markers are supportive but nondiagnostic.
    Interpretation and limitations
    Examples include joint aspiration and culture, vascular ultrasound or biopsy, urinalysis and renal assessment, and targeted imaging; choose according to the threatened organ.
  • 2AlternativeRequest FBC, proteins or disease-specific investigations only when the discordance creates a plausible alternative diagnosis that changes care.
  • 3Document the question for any repeat test and the action threshold, rather than creating indefinite marker surveillance.
    • 03Monitoring known diseaseCombine trend with activity and harmInflammatory markers are being used during treatment of an established rheumatic condition.+
    1. 1Measure at an interval linked to treatment response or safety, using consistent disease-specific clinical and functional assessments.
    2. 2Separate active inflammation from fixed damage, infection, pain amplification and treatment toxicity when markers and symptoms diverge.
    3. 3EscalationEscalate or de-escalate therapy from the integrated assessment and specialist plan, not from a single numerical change.